DiaSorin (OTCMKTS:DSRLF) Rating Increased to Hold at Zacks Research

Zacks Research upgraded shares of DiaSorin (OTCMKTS:DSRLF) to a hold rating in a research report sent to investors on Tuesday morning,Zacks.com reports.

Several other equities research analysts also recently issued reports on the company. UBS Group downgraded DiaSorin from a “buy” rating to a “neutral” rating in a research report on Thursday, April 9th. BNP Paribas Exane upgraded DiaSorin to a “neutral” rating in a research report on Wednesday, January 28th. Finally, Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of DiaSorin in a research report on Tuesday, February 10th. Two investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, DiaSorin has an average rating of “Hold”.

DiaSorin Stock Performance

OTCMKTS:DSRLF opened at $67.00 on Tuesday. The stock’s fifty day moving average price is $71.57 and its two-hundred day moving average price is $75.91. DiaSorin has a 1 year low of $66.50 and a 1 year high of $112.30.

About DiaSorin

DiaSorin S.p.A. is an Italy‐based global biotechnology company specializing in the development, manufacture and marketing of in vitro diagnostic products. Headquartered in Saluggia, DiaSorin serves clinical laboratories, hospitals and physician offices with a broad portfolio of immunodiagnostic assays and molecular diagnostic tests. The company’s shares trade on the Milan Stock Exchange and are available in the United States as over‐the‐counter (OTC) securities under the symbol DSRLF.

At the core of DiaSorin’s business are immunodiagnostic systems that measure antibodies, antigens and hormones in human samples.